Stroope, Chad
Nettersheim, Felix Sebastian http://orcid.org/0000-0002-4090-3357
Coon, Brian http://orcid.org/0000-0002-4516-0193
Finney, Alexandra C. http://orcid.org/0000-0003-1575-4975
Schwartz, Martin A. http://orcid.org/0000-0002-2071-1243
Ley, Klaus http://orcid.org/0000-0001-9339-3672
Rom, Oren http://orcid.org/0000-0002-9272-086X
Yurdagul, Arif Jr. http://orcid.org/0000-0002-7613-6313
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL145131, HL167758, HL135582, HL136275, HL145241, HL150233)
American Heart Association (23POST1026505)
Deutsche Forschungsgemeinschaft (NE 2574/1-1)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK134011)
Article History
Received: 5 March 2023
Accepted: 20 February 2024
First Online: 26 March 2024
Competing interests
: K.L. is founder and co-owner of Atherovax and receives no compensation from Atherovax. No Atherovax funds were used in this study. O.R. is a scientific advisor at Diapin Therapeutics and receives no compensation from Diapin Therapeutics. No Diapin Therapeutics funds were used in this study. All other authors declare no competing interests.